SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy
Megan Durham
Esmo Open
Sodium fluoride (Na18F) PET Response Criteria in Solid Tumors (NAFCIST): a framework for response assessment in bone tumors
Journal of Comparative Effectiveness Research
For what it’s worth: the complex area of medicine value assessment
Annals of Oncology
Searching for clinical trials in oncology: finding a path through the maze
Trends in Cancer
Tumor-agnostic drug development in dMMR/MSI-H solid tumors
European Journal of Cancer
Pooled Safety Analysis of Single-Agent Lurbinectedin in Patients With Advanced Solid Tumours
Nature
Mesothelin-targeting T cell receptor fusion construct cell therapy in refractory solid tumors: phase 1/2 trial interim results
Nature Reviews. Clinical Oncology
Immune-checkpoint inhibition for resectable non-small-cell lung cancer — opportunities and challenges
Annals of Oncology
Weight Gain in Cancer Patients Treated with Brain Penetrant RET-selective Inhibitors
New England Journal of Medicine
Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia